Core Insights - Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for autoimmune diseases and cancers [3] - The company will participate in the Cantor Global Healthcare Conference 2025 on September 3, 2025, at 9:45 a.m. EDT [1] - Artiva's lead program, AlloNK®, is an allogeneic NK cell therapy currently evaluated in three clinical trials targeting B-cell driven autoimmune diseases [3] Company Overview - Artiva Biotherapeutics was founded in 2019 as a spin-out from GC Cell, gaining exclusive worldwide rights to NK cell manufacturing technology [3] - The company is headquartered in San Diego, California [4] - Artiva's pipeline includes CAR-NK candidates aimed at treating both solid and hematologic cancers [3] Conference Participation - Members of Artiva's management team will be available for investor meetings during the conference [2] - A live webcast of the presentation will be accessible through the "Investors" section on Artiva's website, with a replay available for 90 days post-event [2]
Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025